In postmenopausal women, severe energy restriction led to greater weight, fat, and whole-body lean mass loss than that achieved with moderate energy restriction, according to results of the TEMPO* Diet trial conducted in Sydney, Australia. However, there was a tendency toward greater loss in total hip bone mineral density (BMD) with severe energy restriction.
Use of the triplet regimen containing encorafenib, cetuximab and binimetinib, or a doublet regimen containing the first two, confers significant benefits for overall survival and response as compared with standard therapy in the treatment of metastatic colorectal cancer (CRC) harbouring the BRAF V600E mutation, according to the initial results of the phase III, open-label BEACON CRC trial.
Despite a relatively low rate of relapse of intolerance among patients taking pravastatin or fluvastatin, many of them have eventually discontinued or switched to other medication, reveals a study. Relapse is independently predicted by chronic kidney disease and history of creatine kinase elevation.
Low heart rate (HR) in patients with heart failure (HF) and atrial fibrillation (AF) receiving treatment with beta-blockers contributes to an increase in the risk of cardiovascular events, suggesting that a low HR may blunt the beneficial effects of the said drugs, a study has found.
Use of a closed-loop system, also known as the artificial pancreas, led to better glycaemic control in terms of more time spent in the target glycaemic range than a sensor-augmented insulin pump in patients with type 1 diabetes (T1D), according to the iDCL* study.
Using a humanized antidisialoganglioside mAb (hu14.18K322A) in combination with induction chemotherapy appears to yield favourable outcomes in children with high-risk neuroblastoma, including induction of an early response, improvement of Curie scores (CSs) and a 2-year event-free survival (EFS), according to the results of a phase II trial.
Aspirin use does not appear to result in progression of age-related macular degeneration (AMD) or its subtypes in either the Age-Related Eye Disease Study (AREDS) or AREDS2, a study has shown. Thus, there is no need to avoid aspirin use when it is medically indicated in AMD patients.
Treatment with the (ADP-ribose) polymerase (PARP) inhibitor olaparib led to a statistically significant and clinically meaningful improvement in radiological progression-free survival (rPFS) vs physician’s choice of new hormonal agent (NHA) enzalutamide or abiraterone + prednisone in men with advanced prostate cancer harbouring certain gene mutations that were identified through genetic testing, the PROfound* trial has shown.
Twice-a-year injections of the small interfering RNA (siRNA) inclisiran significantly reduced low-density lipoprotein cholesterol (LDL-C) levels in patients with atherosclerotic cardiovascular disease (ASCVD) who have insufficient LDL-C reductions despite maximum oral lipid-lowering therapy, the ORION-10* trial showed.
The combination of glecaprevir and pibrentasvir (G/P) may be a viable option for patients with genotype 1 hepatitis C virus (HCV) infection who had failed prior treatment with sofosbuvir and a nonstructural protein inhibitor, a new study has shown.
New drug applications approved by US FDA as of 16 - 30 November 2018
which includes New Molecular Entities (NMEs) and new biologics. It does
not include Tentative Approvals. Supplemental approvals may have
occurred since the original approval date.
Elvira Manzano, Roshini Claire Anthony,
01 Oct 2019
The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.
Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US.